Your browser version may not work well with NCBI's Web applications. More information here...
1: Breast Cancer Res. 2008;10(5):214. Epub 2008 Oct 31.
Related Articles, Links
Click here to read
Functional genomic analysis of drug sensitivity pathways to guide adjuvant strategies in breast cancer.

Swanton C, Szallasi Z, Brenton JD, Downward J.

Translational Cancer Therapeutics Laboratory, Cancer Research UK London Research Institute, London, UK. charles.swanton@cancer.org.uk

The widespread introduction of high throughput RNA interference screening technology has revealed tumour drug sensitivity pathways to common cytotoxics such as paclitaxel, doxorubicin and 5-fluorouracil, targeted agents such as trastuzumab and inhibitors of AKT and Poly(ADP-ribose) polymerase (PARP) as well as endocrine therapies such as tamoxifen. Given the limited power of microarray signatures to predict therapeutic response in associative studies of small clinical trial cohorts, the use of functional genomic data combined with expression or sequence analysis of genes and microRNAs implicated in drug response in human tumours may provide a more robust method to guide adjuvant treatment strategies in breast cancer that are transferable across different expression platforms and patient cohorts.

Publication Types:
PMID: 18986507 [PubMed - in process]